Translate page

× To share and enhance best practice management of CML, experts and interested clinicians can discuss difficult or interesting CML cases here. Physicians submit a brief history of the patient and the case for discussion (no more than 200 words) by posting it in this forum ("New Discussion" button below). Please include the country of origin.

Each clinical case will be forwarded to the expert clinical panel for a brief independent response. Consideration should be given to patient confidentiality. Details that are not critical to the case can be changed to preserve anonymity. Please consider including your email with the case. This will not be posted on the website, but is useful should further details be requested by the moderator.

As a full clinical history is necessary for accurate comment, cases and comments on the Forum are ONLY ACCEPTED FROM PHYSICIANS. If individual patients have a specific question we encourage them to contact their healthcare provider. General questions can be emailed to info@cml-foundation.org.

DISCLAIMER: The iCMLf does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guaranty as to the same. Reliance on any information provided in this Forum is solely at your own risk.

Molecular monitoring

  • Udani sajitha Kothalawala
  • Udani sajitha Kothalawala's Avatar Topic Author
14 hours 44 minutes ago - 14 hours 30 minutes ago #2094 by Udani sajitha Kothalawala
Molecular monitoring was created by Udani sajitha Kothalawala
Hello,

Recently we have come across a patient with both p210 and p190 transcripts at diagnosis.

What is your experience with a case like this and its molecular monitoring and management considerations?

Awaiting your reply.

Best regards - Udani (Registrar in Haematology, Sri Lanka)
Last edit: 14 hours 30 minutes ago by arlene.
  • Gianantonio Rosti
  • Gianantonio Rosti's Avatar Topic Author
14 hours 23 minutes ago - 14 hours 22 minutes ago #2095 by Gianantonio Rosti
Replied by Gianantonio Rosti on topic Molecular monitoring
"Both p210 and p190" in which %? Generally, p210 is predominant (1-2% of all CP patients may exhibit this association). However, there are data supporting a worse prognosis for patients bearing the association.

Generally, those who progress do so in the early days.

To be practical, in terms of management, there is no strong data in favour of second gen TKIs vs imatinib. Monitoring is as per p210 only patient.
Last edit: 14 hours 22 minutes ago by arlene.
Moderators: Nicolaarlene